These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34083652)

  • 1. DLK1 and Nesfatin-1 levels and the relationship with metabolic parameters in polycystic ovary syndrome: Prospective, controlled study.
    Demir Çaltekin M; Caniklioğlu A; Eris Yalçın S; Aydoğan Kırmızı D; Baser E; Yalvaç ES
    Turk J Obstet Gynecol; 2021 Jun; 18(2):124-130. PubMed ID: 34083652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters.
    Durmus U; Duran C; Ecirli S
    J Endocrinol Invest; 2017 May; 40(5):487-497. PubMed ID: 27838846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment.
    Amato MC; Guarnotta V; Forti D; Donatelli M; Dolcimascolo S; Giordano C
    Hum Reprod; 2013 Jul; 28(7):1919-28. PubMed ID: 23592224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal Serum Delta-Like 1 and Nesfatin-1 Levels in Gestational Diabetes Mellitus: A Prospective Case-Control Study.
    Demir Çaltekin M; Caniklioğlu A
    Cureus; 2021 Aug; 13(8):e17001. PubMed ID: 34540403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nesfatin-1, Dopamine, and NADPH levels in Infertile Women with Polycystic Ovary Syndrome: Is There a Relationship Between Their Levels and Metabolic and Hormonal Variables.
    Hamed EA; Sayyed HG; Abbas AM; Gaber MMA; Aleem HMAE
    J Reprod Infertil; 2022; 23(3):160-168. PubMed ID: 36415498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome.
    Ademoglu EN; Gorar S; Carlıoglu A; Yazıcı H; Dellal FD; Berberoglu Z; Akdeniz D; Uysal S; Karakurt F
    J Endocrinol Invest; 2014 Aug; 37(8):715-719. PubMed ID: 24920281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome.
    Anik Ilhan G; Yildizhan B; Pekin T
    Gynecol Endocrinol; 2019 Mar; 35(3):233-236. PubMed ID: 30303693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
    Singh S; Akhtar N; Ahmad J
    Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleobindin-2 derived nesfatin-1 in polycystic ovary syndrome: a PRISMA and GRADE-compliant systematic review and meta-analysis with diagnostic test accuracy.
    Venkata Nagaraju K; Lisa M; Varikasuvu SR; Kumar S; Singh H; Pérez-López FR; Gupta P; Varshney S
    Minerva Endocrinol (Torino); 2024 Mar; 49(1):111-121. PubMed ID: 37943280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body fat indices as effective predictors of insulin resistance in obese/non-obese polycystic ovary syndrome women in the Southwest of China.
    Huang X; Wang Q; Liu T; Pei T; Liu D; Zhu H; Huang W
    Endocrine; 2019 Jul; 65(1):81-85. PubMed ID: 30924083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between visceral adiposity index, hirsutism and cardiometabolic risk factors in women with polycystic ovarian syndrome: A cross-sectional study.
    Fonseka S; Subhani B; Wijeyaratne CN; Gawarammana IB; Kalupahana NS; Ratnatunga N; Rosairo S; Vithane KP
    Ceylon Med J; 2019 Sep; 64(3):111-117. PubMed ID: 32120461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visceral Adiposity Index: Simple Tool for Assessing Cardiometabolic Risk in Women with Polycystic Ovary Syndrome.
    Agrawal H; Aggarwal K; Jain A
    Indian J Endocrinol Metab; 2019; 23(2):232-237. PubMed ID: 31161109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of various adiposity indexes in women with polycystic ovary syndrome and normo-ovulatory non-hirsute women: a population-based study.
    Ramezani Tehrani F; Minooee S; Azizi F
    Eur J Endocrinol; 2014 Aug; 171(2):199-207. PubMed ID: 24816947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating osteopontin and its association with liver fat content in non-obese women with polycystic ovary syndrome: a case control study.
    Wang Y; Zhou W; Wu C; Zhang Y; Lin T; Sun Y; Liu W; Tao T
    Reprod Biol Endocrinol; 2018 Mar; 16(1):31. PubMed ID: 29587769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome.
    Kurek Eken M; Sahin Ersoy G; Yayla Abide C; Sanverdi İ; Devranoglu B; Kutlu T; Çevik Ö
    J Obstet Gynaecol; 2019 Oct; 39(7):975-980. PubMed ID: 31064233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NUCB2/Nesfatin-1 in the Blood and Follicular Fluid in Patients with Polycystic Ovary Syndrome and Poor Ovarian Response.
    Catak Z; Yavuzkir S; Kocdemir E; Ugur K; Yardim M; Sahin İ; Agirbas EP; Aydin S
    J Reprod Infertil; 2019; 20(4):225-230. PubMed ID: 31897389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating nesfatin-1 levels in women with polycystic ovary syndrome: A systematic review and meta-analysis.
    Sobhan Bahreiny S; Ahangarpour A; Asghar Hemmati A; Kazemzadeh R; Bastani MN; Reza Dabbagh M; Aghaei M
    Int J Reprod Biomed; 2023 Oct; 21(10):777-788. PubMed ID: 38077942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of regional fat mass measurement by whole body DXA scans and anthropometric measures to predict insulin resistance in women with polycystic ovary syndrome and controls.
    Glintborg D; Petersen MH; Ravn P; Hermann AP; Andersen M
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1235-1243. PubMed ID: 27529295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is prolactin the missing link in adipose tissue dysfunction of polycystic ovary syndrome patients?
    Albu A; Florea S; Fica S
    Endocrine; 2016 Jan; 51(1):163-73. PubMed ID: 26067083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome.
    Androulakis II; Kandaraki E; Christakou C; Karachalios A; Marinakis E; Paterakis T; Diamanti-Kandarakis E
    Clin Endocrinol (Oxf); 2014 Sep; 81(3):426-31. PubMed ID: 24601936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.